Search…

Daiichi Sankyo Yuhan and Pfizer's new indication for patritumab deruxtecan has been approved in China.

12/08/2026

On August 12, Daiichi Sankyo announced that the new indication for Enhertu has been approved in China. The approved indication is: this product in combination with patritumab is indicated for first-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer.

Latest

2 m ago

Tencent stated in its financial report that the Hunyuan Hy3 has completed a rapid iteration from preview to official version, with the call volume increasing by more than 68 times in the week since its launch compared to the previous generation model. A larger parameter version, Hy4, is also planned for release soon.

2 m ago

Haichuan Cement (00914.HK) spent 17.2449 million yuan on August 12 to repurchase 980,000 shares of A-shares.

2 m ago

The Hong Kong Electric Holdings Limited (00006.HK) announced its interim results, with a profit attributable to shareholders of HKD 14.704 billion, an increase of 383.37% year-on-year.

3 m ago

In the first quarter, Sharp Corporation's revenue reached 435.2 billion yen, compared to 472.49 billion yen. The earnings per share for the first quarter was 4.80 yen, down from 41.95 yen in the same period last year.

3 m ago

Electric Power Industry (00006.HK) will distribute an interim dividend of HK$0.78 per share on September 22.

See all latest